Transcode Therapeutics RNAZ

NASDAQ RNAZ

$1.78 -0.11 (-5.82%)

At close: Sep 9, 2026 · 4:00 PM EDT

Key Stats

Market Cap1.79 Mn

P/E-0.04

Div. Yield0.00

Total Debt (Qtr)652,411.00

Add ratio to table…

About

TransCode Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers. The company leverages its proprietary TTX drug design engine to overcome delivery challenges associated with oligonucleotide therapeutics, enabling targeted delivery to tumors and metastases. Its pipeline includes TTX-MC138, an antisense inhibitor of microRNA-10b, Seviprotimut-L, a…

TransCode Therapeutics generates revenue primarily through potential future commercialization of its therapeutic candidates, as it currently has no marketed products or sales revenue. The company relies on funding from strategic investments, licensing agreements, and equity issuances to support research and development activities. Revenue generation is anticipated upon regulatory approval and successful clinical development of its lead programs, including TTX-MC138 and Seviprotimut-L.

The company operates through the following segments:

TTX-MC138 Program: This segment focuses on the development of TTX-MC138, an antisense oligonucleotide therapeutic targeting microRNA-10b for the treatment of metastatic cancers. TTX-MC138 is designed to inhibit miR-10b, a master regulator of metastatic cell viability, and has completed Phase 1a clinical testing. The program utilizes the TTX drug delivery platform to enhance tumor targeting and therapeutic payload delivery.
Seviprotimut-L Program: This segment encompasses the development of Seviprotimut-L, a polyvalent shed antigen vaccine derived from three human melanoma cell lines (SFHM2, SFHM4, SFHM8) and adjuvanted with alum. Seviprotimut-L has received FDA Fast Track designation and is being evaluated for adjuvant treatment of Stage IIB and IIC melanoma to reduce recurrence risk. The vaccine stimulates both humoral and cellular immune responses against melanoma-associated antigens.
Unleash Oncolytic Immunotherapy Platform: This segment includes the rights to UIO-524, UIO-525, and UIO-526, a pipeline of genetically engineered oncolytic adenoviruses acquired via the Unleash Licensing Agreement. UIO-524, the lead candidate, is designed to replicate in malignant cells and cancer-associated stroma while delivering a multi-cytokine payload (CD40-L, 4-1BBL, IL-21) to activate dendritic cells, T cells, and NK cells. The platform is being developed initially for muscle-invasive bladder cancer (MIBC).

TransCode Therapeutics holds a differentiated position in the oncology therapeutics industry due to its TTX drug design engine, which enables precise delivery of RNA-based therapies to tumors and metastases—a challenge not effectively addressed by conventional lipid nanoparticle systems. The company competes with other RNA-focused therapeutics developers such as Alnylam, Ionis, Moderna, and BioNTech, but distinguishes itself through its exclusive focus on oncology, multimodal pipeline (including antisense, siRNA, RNA vaccines, and immunostimulatory RNAs), and imaging-guided delivery capabilities. Its competitive advantages include the ability to achieve robust target engagement in tumor cells, an anticipated wide therapeutic window, and the use of MRI for noninvasive monitoring of drug delivery.

TransCode Therapeutics serves patients with advanced solid tumors, particularly those with metastatic melanoma, pancreatic adenocarcinoma, breast cancer, and muscle-invasive bladder cancer. The company’s therapeutic candidates are intended for individuals who have undergone surgical resection and are at high risk of recurrence or have limited treatment options. Clinical trials are conducted in collaboration with major cancer centers such as Massachusetts General Hospital and MD Anderson Cancer Center, targeting enrolled patients with specific disease indications and biomarker profiles.

Investment Thesis

▲ Bull case

TransCode Therapeutics is advancing a highly differentiated therapeutic platform centered on TTX-MC138, a first-in-class microRNA-10b inhibitor with demonstrated safety and biological activity in Phase 1a trials, including durable disease stabilization in 64% of evaluable metastatic patients and no dose-limiting toxicities across multiple dosing cohorts, which provides a strong foundation for Phase 2a efficacy evaluation in the minimal residual disease setting where intervention timing is critical for long-term outcomes.
The initiation of the Phase 2a clinical trial in ctDNA-positive colorectal cancer patients following curative-intent therapy represents a strategic pivot toward earlier intervention in the disease continuum, leveraging the growing clinical validation of ctDNA as a sensitive biomarker for minimal residual disease, and positions TransCode to potentially prevent metastatic recurrence in a high-risk population where current adjuvant therapies often fail, thereby addressing a significant unmet need in oncology.
Expansion of the pipeline through the exclusive worldwide license agreement with Unleash Immuno Oncolytics for UIO-524, UIO-525, and UIO-526 introduces a next-generation oncolytic immunotherapy platform targeting muscle-invasive bladder cancer — a multi-billion-dollar market with limited durable options — thereby diversifying risk beyond TTX-MC138 and providing multiple near-term catalysts for clinical advancement in additional high-unmet-need indications.
The $20 million financing agreement, comprising $6 million in pre-paid advances and a $14 million Standby Equity Purchase Agreement, provides TransCode with non-dilutive runway to complete the Phase 2a trial and explore strategic collaborations, alleviating near-term liquidity concerns and enabling the company to maintain operational momentum without immediate pressure to raise additional capital at potentially unfavorable terms.
Preclinical evidence supporting TTX-MC138’s potential in glioblastoma multiforme, including sustained target engagement, five-fold induction of apoptotic activity, and statistically significant survival improvement in orthotopic models, combined with prior IND-enabling studies and Phase 1a safety data, supports the rationale for expanding into CNS malignancies — a notoriously difficult-to-treat space — thereby unlocking additional value beyond the current colorectal cancer focus and validating the broad applicability of the TTX delivery platform.

TransCode Therapeutics is advancing a highly differentiated therapeutic platform centered on TTX-MC138, a first-in-class microRNA-10b inhibitor with demonstrated safety and biological activity in Phase 1a trials, including durable disease stabilization in 64% of evaluable metastatic patients and no dose-limiting toxicities across multiple dosing cohorts, which provides a strong foundation for Phase 2a efficacy evaluation in the minimal residual disease setting where intervention timing is critical for long-term outcomes.
The initiation of the Phase 2a clinical trial in ctDNA-positive colorectal cancer patients following curative-intent therapy represents a strategic pivot toward earlier intervention in the disease continuum, leveraging the growing clinical validation of ctDNA as a sensitive biomarker for minimal residual disease, and positions TransCode to potentially prevent metastatic recurrence in a high-risk population where current adjuvant therapies often fail, thereby addressing a significant unmet need in oncology.
Expansion of the pipeline through the exclusive worldwide license agreement with Unleash Immuno Oncolytics for UIO-524, UIO-525, and UIO-526 introduces a next-generation oncolytic immunotherapy platform targeting muscle-invasive bladder cancer — a multi-billion-dollar market with limited durable options — thereby diversifying risk beyond TTX-MC138 and providing multiple near-term catalysts for clinical advancement in additional high-unmet-need indications.
The $20 million financing agreement, comprising $6 million in pre-paid advances and a $14 million Standby Equity Purchase Agreement, provides TransCode with non-dilutive runway to complete the Phase 2a trial and explore strategic collaborations, alleviating near-term liquidity concerns and enabling the company to maintain operational momentum without immediate pressure to raise additional capital at potentially unfavorable terms.
Preclinical evidence supporting TTX-MC138’s potential in glioblastoma multiforme, including sustained target engagement, five-fold induction of apoptotic activity, and statistically significant survival improvement in orthotopic models, combined with prior IND-enabling studies and Phase 1a safety data, supports the rationale for expanding into CNS malignancies — a notoriously difficult-to-treat space — thereby unlocking additional value beyond the current colorectal cancer focus and validating the broad applicability of the TTX delivery platform.

▼ Bear case

TransCode Therapeutics remains a pre-revenue clinical-stage company with no approved products, and despite positive Phase 1a safety data, the company has not yet demonstrated efficacy in any pivotal trial, meaning the current valuation may be overly dependent on speculative success in the Phase 2a ctDNA-positive colorectal cancer trial, which carries inherent risks of failure due to modest patient enrollment (up to 45 patients), heterogeneous ctDNA dynamics, and the lack of a validated surrogate endpoint for minimal residual disease intervention in this setting.
The company’s reliance on third-party collaborators such as Quantum Leap Healthcare Collaborative and Michigan State University for trial execution, site access, and preclinical research introduces operational dependency and potential delays, as any misalignment in priorities, funding, or regulatory readiness among partners could impede trial timelines or data readouts, particularly given the complexity of ctDNA-guided trial designs requiring frequent serial biomarker monitoring.
While the Unleash licensing deal expands the pipeline, the candidates (UIO-524/525/526) remain in preclinical stages with no IND-enabling data disclosed, and the one-time payment of preferred stock representing 6.8% of fully diluted shares introduces potential future dilution upon conversion, which could weigh on existing shareholders if the licensed programs fail to meet preclinical milestones or require substantial additional investment to advance.
The $20 million financing arrangement, though providing near-term relief, includes convertible notes and a SEPA that could lead to significant shareholder dilution if triggered, especially if the company’s stock price underperforms due to clinical delays or negative data, forcing TransCode to sell shares at a discount to raise the full $14 million, thereby exacerbating downward pressure on the stock.
The broader oncology landscape is increasingly competitive in both RNA therapeutics and immuno-oncology, with multiple larger players pursuing similar targets (e.g., miR-10b inhibitors, ctDNA-guided therapies, oncolytic viruses), and TransCode’s lack of scale, limited cash runway beyond the financed amount, and absence of commercial infrastructure increase the risk of being outpaced by better-resourced competitors who could replicate or surpass its approach before TransCode achieves clinical proof of concept.

TransCode Therapeutics remains a pre-revenue clinical-stage company with no approved products, and despite positive Phase 1a safety data, the company has not yet demonstrated efficacy in any pivotal trial, meaning the current valuation may be overly dependent on speculative success in the Phase 2a ctDNA-positive colorectal cancer trial, which carries inherent risks of failure due to modest patient enrollment (up to 45 patients), heterogeneous ctDNA dynamics, and the lack of a validated surrogate endpoint for minimal residual disease intervention in this setting.
The company’s reliance on third-party collaborators such as Quantum Leap Healthcare Collaborative and Michigan State University for trial execution, site access, and preclinical research introduces operational dependency and potential delays, as any misalignment in priorities, funding, or regulatory readiness among partners could impede trial timelines or data readouts, particularly given the complexity of ctDNA-guided trial designs requiring frequent serial biomarker monitoring.
While the Unleash licensing deal expands the pipeline, the candidates (UIO-524/525/526) remain in preclinical stages with no IND-enabling data disclosed, and the one-time payment of preferred stock representing 6.8% of fully diluted shares introduces potential future dilution upon conversion, which could weigh on existing shareholders if the licensed programs fail to meet preclinical milestones or require substantial additional investment to advance.
The $20 million financing arrangement, though providing near-term relief, includes convertible notes and a SEPA that could lead to significant shareholder dilution if triggered, especially if the company’s stock price underperforms due to clinical delays or negative data, forcing TransCode to sell shares at a discount to raise the full $14 million, thereby exacerbating downward pressure on the stock.
The broader oncology landscape is increasingly competitive in both RNA therapeutics and immuno-oncology, with multiple larger players pursuing similar targets (e.g., miR-10b inhibitors, ctDNA-guided therapies, oncolytic viruses), and TransCode’s lack of scale, limited cash runway beyond the financed amount, and absence of commercial infrastructure increase the risk of being outpaced by better-resourced competitors who could replicate or surpass its approach before TransCode achieves clinical proof of concept.

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

Transcode Therapeutics RNAZ

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password